VENUS MEDTECH-B

2500
0.9900.00% ( 0.000 )
Delay Closed: Nov 16, 16:08:00

Overview

VENUS MEDTECH-B (2500)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Ma...

Open
1.000
High
1.000
Low
0.970
Prev. Close
0.990
Volume
733.50K
Turnover
726.30K
Avg Price
0.990
Bid/Ask Ratio
-66.07%
Amplitude
3.03%
52wk High
3.860
Volume Ratio
0.91
Turnover Ratio
0.17%
52wk Low
0.940
HK Mkt Cap
436.60M
Market CapHKD
436.60M
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-1.21
EPSDynamic
-0.999
EPSStatic
--
BVPS
3.98
P/B
0.25
HK Shares
441.01M
Dividend YieldTTM
--
DividendTTM
--
Shares
441.01M
Min lot size
500
Currency
HKD

VENUS MEDTECH-B Analyst Rating

View more

Forecast & Rating

Nov 11, 2025
Price forecast
HK$4.30334.33%
Forecast & Rating-

Daily Events

  1. Jul, 3

    Venus Medtech surged 28.2% in heavy volume to close at HKD 1.73, driven by Cardiovalve CE marking submission and completion of the 150-patient TARGET study enrollment. The stock opened at HKD 1.27, rallied to an intraday high of HKD 1.82 before paring gains, resulting in a 42.5% daily range. Despite a 48% YoY revenue decline to HKD 66.5 million, net loss per share improved 44% to HKD -0.35. The stock now trades 63% above its 52-week low of HKD 1.06 and sits above both the 20-day (HKD 1.27) and 60-day (HKD 1.59) moving averages, though still 69% below the 52-week high of HKD 5.47. Year-to-date the stock is down 30%, while the company has divested a Hangzhou industrial property and a minority investment totaling approximately HKD 525 million to refocus on its valve business.

News